HDGF: A novel jack-of-all-trades in cancer

Future Oncology

Volumn 10, Issue 16, 2014, Pages 2675-2685

  Bao, Cihang ^a   Wang, Jianbo ^a   Ma, Wei ^b   Wang, Xintong ^a   Cheng, Yufeng ^a  

^a SHANDONG UNIVERSITY   (China)

^b NINGXIA MEDICAL UNIVERSITY   (China)

Author keywords

angiogenesis; apoptosis; epithelial to mesencyhmal transition; hepatoma derived growth factor; metastasis; molecular mechanisms; prognosis; PWWP HATH domain; serum levels; tumorigenesis

Indexed keywords

BIOLOGICAL MARKER; HEPATOMA DERIVED GROWTH FACTOR;

ANGIOGENESIS; APOPTOSIS; BLOOD LEVEL; CANCER CELL; CANCER GROWTH; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER THERAPY; CARCINOGENESIS; CELL ACTIVITY; CELLULAR DISTRIBUTION; HUMAN; MALIGNANT NEOPLASTIC DISEASE; METASTASIS; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN STRUCTURE; REVIEW;

EID: 84919786450     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.14.194     Document Type: Review

References (97)

1. Klagsbrun M, Sasse J, Sullivan R, Smith JA. Human tumor cells synthesize an endothelial cell growth factor that is structurally related to basic fibroblast growth factor. Proc. Natl Acad. Sci. USA 83(8), 2448-2452 (1986).
2. Oliver JA, Al-Awqati Q. An endothelial growth factor involved in rat renal development. J. Clin. Invest. 102(6), 1208-1219 (1998).
3. Enomoto H, Yoshida K, Kishima Y et al. Hepatoma-derived growth factor is highly expressed in developing liver and promotes fetal hepatocyte proliferation. Hepatology 36(6), 1519-1527 (2002).
4. Everett AD. Identification, cloning, and developmental expression of hepatoma-derived growth factor in the developing rat heart. Dev. Dyn. 222(3), 450-458 (2001).
5. Enomoto H, Nakamura H, Liu W et al. Hepatoma-derived growth factor is induced in liver regeneration. Hepatol. Res. 39(10), 988-997 (2009).
6. Kung ML, Tsai HE, Hu TH et al. Hepatoma-derived growth factor stimulates podosome rosettes formation in NIH/3T3 cells through the activation of phosphatidylinositol 3-kinase/Akt pathway. Biochem. Biophys. Res. Commun. 425(2), 169-176 (2012).
7. Zhou Z, Yamamoto Y, Sugai F et al. Hepatoma-derived growth factor is a neurotrophic factor harbored in the nucleus. J. Biol. Chem. 279(26), 27320-27326 (2004).
8. Hollander A, D'Onofrio PM, Magharious MM, Lysko MD, Koeberle PD. Quantitative retinal protein analysis after optic nerve transection reveals a neuroprotective role for hepatoma-derived growth factor on injured retinal ganglion cells. Invest. Ophthalmol. Vis. Sci. 53(7), 3973-3989 (2012).
9. Everett AD, Lobe DR, Matsumura ME, Nakamura H, McNamara CA. Hepatoma-derived growth factor stimulates smooth muscle cell growth and is expressed in vascular development. J. Clin. Invest. 105(5), 567-575 (2000).
10. Everett AD, Narron JV, Stoops T, Nakamura H, Tucker A. Hepatoma-derived growth factor is a pulmonary endothelial cell-expressed angiogenic factor. Am. J. Physiol. Lung Cell. Mol. Physiol. 286(6), L1194-1201 (2004).
11. Matsuyama A, Inoue H, Shibuta K et al. Hepatoma-derived growth factor is associated with reduced sensitivity to irradiation in esophageal cancer. Cancer Res. 61(15), 5714-5717 (2001).
12. Liao F, Liu M, Lv L, Dong W. Hepatoma-derived growth factor promotes the resistance to anti-Tumor effects of nordihydroguaiaretic acid in colorectal cancer cells. Eur. J. Pharmacol. 645(1-3), 55-62 (2010).
13. Everett AD, Yang J, Rahman M, Dulloor P, Brautigan DL. Mitotic phosphorylation activates hepatoma-derived growth factor as a mitogen. BMC Cell Biol. 12, 15 (2011).
14. Yang J, Everett AD. Hepatoma-derived growth factor binds DNA through the N-Terminal PWWP domain. BMC Mol. Biol. 8, 101 (2007).
15. Yang J, Everett AD. Hepatoma-derived growth factor represses SET and MYND domain containing 1 gene expression through interaction with C-Terminal binding protein. J. Mol. Biol. 386(4), 938-950 (2009).
16. Clermont F, Gonzalez NS, Communi D, Franken S, Dumont JE, Robaye B. HDGF is dephosphorylated during the early steps of endothelial cell apoptosis in a caspase-dependent way. J. Cell. Biochem. 104(4), 1161-1171 (2008).
17. Stec I, Nagl SB, Van Ommen GJ, Den Dunnen JT. The PWWP domain: A potential protein-protein interaction domain in nuclear proteins influencing differentiation? FEBS Lett. 473(1), 1-5 (2000).
18. Chen SC, Kung ML, Hu TH et al. Hepatoma-derived growth factor regulates breast cancer cell invasion by modulating epithelial-mesenchymal transition. J. Pathol. 228(2), 158-169 (2012).
19. Wang CH, Davamani F, Sue SC et al. Cell surface heparan sulfates mediate internalization of the PWWP/HATH domain of HDGF via macropinocytosis to fine-Tune cell signalling processes involved in fibroblast cell migration. Biochem. J. 433(1), 127-138 (2011).
20. Wanschura S, Schoenmakers EF, Huysmans C, Bartnitzke S, Van De Ven WJ, Bullerdiek J. Mapping of the gene encoding the human hepatoma-derived growth factor (HDGF) with homology to the high-mobility group (HMG)-1 protein to Xq25. Genomics 32(2), 298-300 (1996).
21. Huang JS, Chao CC, Su TL et al. Diverse cellular transformation capability of overexpressed genes in human hepatocellular carcinoma. Biochem. Biophys. Res. Commun. 315(4), 950-958 (2004).
22. Natrajan R, Williams RD, Hing SN et al. Array CGH profiling of favourable histology Wilms tumours reveals novel gains and losses associated with relapse. J. Pathol. 210(1), 49-58 (2006).
23. Sue SC, Chen JY, Lee SC, Wu WG, Huang TH. Solution structure and heparin interaction of human hepatoma-derived growth factor. J. Mol. Biol. 343(5), 1365-1377 (2004).
24. Sue SC, Lee WT, Tien SC et al. PWWP module of human hepatoma-derived growth factor forms a domain-swapped dimer with much higher affinity for heparin. J. Mol. Biol. 367(2), 456-472 (2007).
25. Lukasik SM, Cierpicki T, Borloz M, Grembecka J, Everett A, Bushweller JH. High resolution structure of the HDGF PWWP domain: A potential DNA binding domain. Protein Sci. 15(2), 314-323 (2006).
26. Zhao J, Yu H, Lin L et al. Interactome study suggests multiple cellular functions of hepatoma-derived growth factor (HDGF). J. Proteomics 75(2), 588-602 (2011).
27. Lepourcelet M, Tou L, Cai L et al. Insights into developmental mechanisms and cancers in the mammalian intestine derived from serial analysis of gene expression and study of the hepatoma-derived growth factor (HDGF). Development 132(2), 415-427 (2005).
28. Bremer S, Klein K, Sedlmaier A, Abouzied M, Gieselmann V, Franken S. Hepatoma-derived growth factor and nucleolin exist in the same ribonucleoprotein complex. BMC Biochem. 14, 2 (2013).
29. Abouzied MM, El-Tahir HM, Prenner L, Haberlein H, Gieselmann V, Franken S. Hepatoma-derived growth factor. Significance of amino acid residues 81-100 in cell surface interaction and proliferative activity. J. Biol. Chem. 280(12), 10945-10954 (2005).
30. Kishima Y, Yamamoto H, Izumoto Y et al. Hepatoma-derived growth factor stimulates cell growth after translocation to the nucleus by nuclear localization signals. J. Biol. Chem. 277(12), 10315-10322 (2002).
31. Thakar K, Krocher T, Savant S, Gollnast D, Kelm S, Dietz F. Secretion of hepatoma-derived growth factor is regulated by N-Terminal processing. Biol. Chem. 391(12), 1401-1410 (2010).
32. Mosevitsky MI, Novitskaya VA, Iogannsen MG, Zabezhinsky MA. Tissue specificity of nucleo-cytoplasmic distribution of HMG1 and HMG2 proteins and their probable functions. Eur. J. Biochem. 185(2), 303-310 (1989).
33. Ooi BN, Mukhopadhyay A, Masilamani J et al. Hepatoma-derived growth factor and its role in keloid pathogenesis. J. Cell. Mol. Med. 14(6A), 1328-1337 (2010).
34. Nakamura H, Izumoto Y, Kambe H et al. Molecular cloning of complementary DNA for a novel human hepatoma-derived growth factor. Its homology with high mobility group-1 protein. J. Biol. Chem. 269(40), 25143-25149 (1994).
35. Zhang J, Ren H, Yuan P, Lang W, Zhang L, Mao L. Down-regulation of hepatoma-derived growth factor inhibits anchorage-independent growth and invasion of non-small cell lung cancer cells. Cancer Res. 66(1), 18-23 (2006).
36. Ren H, Chu Z, Mao L. Antibodies targeting hepatoma-derived growth factor as a novel strategy in treating lung cancer. Mol. Cancer Ther. 8(5), 1106-1112 (2009).
37. Lee KH, Choi EY, Kim MK et al. Hepatoma-derived growth factor regulates the bad-mediated apoptotic pathway and induction of vascular endothelial growth factor in stomach cancer cells. Oncol. Res. 19(2), 67-76 (2010).
38. Zhou Y, Zhou N, Fang W, Huo J. Overexpressed HDGF as an independent prognostic factor is involved in poor prognosis in Chinese patients with liver cancer. Diagn. Pathol. 5, 58 (2010).
39. Guo Z, He Y, Wang S et al. Various effects of hepatoma-derived growth factor on cell growth, migration and invasion of breast cancer and prostate cancer cells. Oncol. Rep. 26(2), 511-517 (2011).
40. Arvizo RR, Giri K, Moyano D et al. Identifying new therapeutic targets via modulation of protein corona formation by engineered nanoparticles. PLoS ONE 7(3), e33650 (2012).
41. Hsu SS, Chen CH, Liu GS et al. Tumorigenesis and prognostic role of hepatoma-derived growth factor in human gliomas. J. Neurooncol. 107(1), 101-109 (2012).
42. Zhang A, Long W, Guo Z, Cao BB. Downregulation of hepatoma-derived growth factor suppresses the malignant phenotype of U87 human glioma cells. Oncol. Rep. 28(1), 62-68 (2012).
43. Li M, Shen J, Wu X et al. Downregulated expression of hepatoma-derived growth factor (HDGF) reduces gallbladder cancer cell proliferation and invasion. Med. Oncol. 30(2), 587 (2013).
44. Tsai HE, Wu JC, Kung ML et al. Up-regulation of hepatoma-derived growth factor facilitates tumor progression in malignant melanoma [corrected]. PLoS ONE 8(3), e59345 (2013).
45. Yang Y, Li H, Zhang F et al. Clinical and biological significance of hepatoma-derived growth factor in Ewing's sarcoma. J. Pathol. 231(3), 323-334 (2013).
46. Tsang TY, Tang WY, Tsang WP, Co NN, Kong SK, Kwok TT. Mechanistic study on growth suppression and apoptosis induction by targeting hepatoma-derived growth factor in human hepatocellular carcinoma HepG2 cells. Cell. Physiol. Biochem. 24(3-4), 253-262 (2009).
47. Zhou SJ, Xu SF, Zhang HQ, Liu ZD. Expression of HDGF and its implication in stage I non-small cell lung cancer. Zhonghua Zhong Liu Za Zhi 29(12), 927-930 (2007).
48. Chang KC, Tai MH, Lin JW et al. Hepatoma-derived growth factor is a novel prognostic factor for gastrointestinal stromal tumors. Int. J. Cancer 121(5), 1059-1065 (2007).
49. Mao J, Xu Z, Fang Y et al. Hepatoma-derived growth factor involved in the carcinogenesis of gastric epithelial cells through promotion of cell proliferation by Erk1/2 activation. Cancer Sci. 99(11), 2120-2127 (2008).
50. Yoshida K, Nakamura H, Okuda Y et al. Expression of hepatoma-derived growth factor in hepatocarcinogenesis. J. Gastroenterol. Hepatol. 18(11), 1293-1301 (2003).
51. Hu TH, Huang CC, Liu LF et al. Expression of hepatoma-derived growth factor in hepatocellular carcinoma. Cancer 98(7), 1444-1456 (2003).
52. Meng J, Xie W, Cao L, Hu C, Zhe Z. shRNA targeting HDGF suppressed cell growth and invasion of squamous cell lung cancer. Acta Biochim. Biophys. Sin. (Shanghai) 42(1), 52-57 (2010).
53. Hayashi E, Kuramitsu Y, Okada F et al. Proteomic profiling for cancer progression: Differential display analysis for the expression of intracellular proteins between regressive and progressive cancer cell lines. Proteomics 5(4), 1024-1032 (2005).
54. Yoshida K, Tomita Y, Okuda Y et al. Hepatoma-derived growth factor is a novel prognostic factor for hepatocellular carcinoma. Ann. Surg. Oncol. 13(2), 159-167 (2006).
55. Maschietto M, Trape AP, Piccoli FS et al. Temporal blastemal cell gene expression analysis in the kidney reveals new Wnt and related signaling pathway genes to be essential for Wilms' tumor onset. Cell Death Dis. 2, e224 (2011).
56. Sedlmaier A, Wernert N, Gallitzendorfer R, Abouzied MM, Gieselmann V, Franken S. Overexpression of hepatoma-derived growth factor in melanocytes does not lead to oncogenic transformation. BMC Cancer 11, 457 (2011).
57. Bernard K, Litman E, Fitzpatrick JL et al. Functional proteomic analysis of melanoma progression. Cancer Res. 63(20), 6716-6725 (2003).
58. Sasaki Y, Negishi H, Idogawa M et al. p53 negatively regulates the hepatoma growth factor HDGF. Cancer Res. 71(22), 7038-7047 (2011).
59. Ke Y, Zhao W, Xiong J, Cao R. Downregulation of miR-16 promotes growth and motility by targeting HDGF in non-small cell lung cancer cells. FEBS Lett. 587(18), 3153-3157 (2013).
60. Chen B, Huang T, Jiang J, Lv L, Li H, Xia S. miR-141 suppresses proliferation and motility of gastric cancer cells by targeting HDGF. Mol. Cell. Biochem. 388(1-2), 211-218 (2014).
61. Guo H, Li W, Zheng T, Liu Z. miR-195 targets HDGF to inhibit proliferation and invasion of NSCLC cells. Tumour Biol. doi:10.1007/s13277-014-2153-0 (2014) (Epub ahead of print).
62. Zhao WY, Wang Y, An ZJ et al. Downregulation of miR-497 promotes tumor growth and angiogenesis by targeting HDGF in non-small cell lung cancer. Biochem. Biophys. Res. Commun. 435(3), 466-471 (2013).
63. Machuy N, Thiede B, Rajalingam K et al. A global approach combining proteome analysis and phenotypic screening with RNA interference yields novel apoptosis regulators. Mol. Cell. Proteomics 4(1), 44-55 (2005).
64. Micheau O, Tschopp J. Induction of TNF receptor I-mediated apoptosis via two sequential signaling complexes. Cell 114(2), 181-190 (2003).
65. Deng Y, Ren X, Yang L, Lin Y, Wu X. A JNK-dependent pathway is required for TNFalpha-induced apoptosis. Cell 115(1), 61-70 (2003).
66. Yu Y, Shen H, Yu H et al. Systematic proteomic analysis of human hepotacellular carcinoma cells reveals molecular pathways and networks involved in metastasis. Mol. Biosyst. 7(6), 1908-1916 (2011).
67. Tsang TY, Tang WY, Tsang WP, Co NN, Kong SK, Kwok TT. Downregulation of hepatoma-derived growth factor activates the Bad-mediated apoptotic pathway in human cancer cells. Apoptosis 13(9), 1135-1147 (2008).
68. Liao F, Dong W, Fan L. Apoptosis of human colorectal carcinoma cells is induced by blocking hepatoma-derived growth factor. Med. Oncol. 27(4), 1219-1226 (2010).
69. Thirant C, Galan-Moya EM, Dubois LG et al. Differential proteomic analysis of human glioblastoma and neural stem cells reveals HDGF as a novel angiogenic secreted factor. Stem Cells 30(5), 845-853 (2012).
70. Li D, Han Z, Liu J et al. Upregulation of nucleus HDGF predicts poor prognostic outcome in patients with penile squamous cell carcinoma bypass VEGF-A and Ki-67. Med. Oncol. 30(4), 702 (2013).
71. Han Y, Zhang W, Liu Y. Identification of hepatoma-derived growth factor as a potential prognostic and diagnostic marker for extrahepatic cholangiocarcinoma. World J. Surg. 37(10), 2419-2427 (2013).
72. Li SZ, Zhao YB, Cao WD et al. The expression of hepatoma-derived growth factor in primary central nervous system lymphoma and its correlation with angiogenesis, proliferation and clinical outcome. Med. Oncol. 30(3), 622 (2013).
73. Liu YF, Zhao R, Guo S et al. Expression and clinical significance of hepatoma-derived growth factor as a prognostic factor in human hilar cholangiocarcinoma. Ann. Surg. Oncol. 18(3), 872-879 (2011).
74. Shih TC, Tien YJ, Wen CJ et al. MicroRNA-214 downregulation contributes to tumor angiogenesis by inducing secretion of the hepatoma-derived growth factor in human hepatoma. J. Hepatol. 57(3), 584-591 (2012).
75. Yamamoto S, Tomita Y, Hoshida Y et al. Expression level of hepatoma-derived growth factor correlates with tumor recurrence of esophageal carcinoma. Ann. Surg. Oncol. 14(7), 2141-2149 (2007).
76. Tsai HE, Liu GS, Kung ML et al. Downregulation of hepatoma-derived growth factor contributes to retarded lung metastasis via inhibition of epithelial-mesenchymal transition by systemic POMC gene delivery in melanoma. Mol. Cancer Ther. 12(6), 1016-1025 (2013).
77. Zhang J, Chen N, Qi J, Zhou B, Qiu X. HDGF and ADAM9 are novel molecular staging biomarkers, prognostic biomarkers and predictive biomarkers for adjuvant chemotherapy in surgically resected stage I non-small cell lung cancer. J. Cancer Res. Clin. Oncol. 140(8), 1441-1449 (2014).
78. Savola S, Klami A, Tripathi A et al. Combined use of expression and CGH arrays pinpoints novel candidate genes in Ewing sarcoma family of tumors. BMC Cancer 9, 17 (2009).
79. Yang Y, Zhen T, Zhang F et al. p53 and hepatoma-derived growth factor expression and their clinicopathological association with Ewing family tumour. J. Clin. Pathol. 67(3), 235-242 (2014).
80. Chen X, Yun J, Fei F et al. Prognostic value of nuclear hepatoma-derived growth factor (HDGF) localization in patients with breast cancer. Pathol. Res. Pract. 208(8), 437-443 (2012).
81. Lin YW, Li CF, Chen HY et al. The expression and prognostic significance of hepatoma-derived growth factor in oral cancer. Oral Oncol. 48(7), 629-635 (2012).
82. Yamamoto S, Tomita Y, Hoshida Y et al. Expression of hepatoma-derived growth factor is correlated with lymph node metastasis and prognosis of gastric carcinoma. Clin. Cancer Res. 12(1), 117-122 (2006).
83. Uyama H, Tomita Y, Nakamura H et al. Hepatoma-derived growth factor is a novel prognostic factor for patients with pancreatic cancer. Clin. Cancer Res. 12(20 Pt 1), 6043-6048 (2006).
84. Wang S, Fang W. Increased expression of hepatoma-derived growth factor correlates with poor prognosis in human nasopharyngeal carcinoma. Histopathology 58(2), 217-224 (2011).
85. Ren H, Tang X, Lee JJ et al. Expression of hepatoma-derived growth factor is a strong prognostic predictor for patients with early-stage non-small-cell lung cancer. J. Clin. Oncol. 22(16), 3230-3237 (2004).
86. Meng J, Cao LM, Hu CP, Zhen ZY. Establishment of a lung adenocarcinoma cell line stably expressing small interfering RNA targeting hepatoma-derived growth factor and detection of interference effect. Nan Fang Yi Ke Da Xue Xue Bao 29(11), 2233-2236 (2009).
87. Zhang A, Long W, Guo Z et al. Development and clinical evaluation of a multi-purpose mAb and a sandwich ELISA test for hepatoma-derived growth factor in lung cancer patients. J. Immunol. Methods 355(1-2), 61-67 (2010).
88. Zhang J, Qi J, Guo Y et al. Aberrant expression of HDGF and its prognostic values in surgically resected non-small cell lung cancer. Zhongguo Fei Ai Za Zhi 14(3), 211-218 (2011).
89. Iwasaki T, Nakagawa K, Nakamura H, Takada Y, Matsui K, Kawahara K. Hepatoma-derived growth factor as a prognostic marker in completely resected non-small-cell lung cancer. Oncol. Rep. 13(6), 1075-1080 (2005).
90. Hu TH, Lin JW, Chen HH, Liu LF, Chuah SK, Tai MH. The expression and prognostic role of hepatoma-derived growth factor in colorectal stromal tumors. Dis. Colon Rectum 52(2), 319-326 (2009).
91. Wang L, Jiang Q, Hua S et al. High nuclear expression of HDGF correlates with disease progression and poor prognosis in human endometrial carcinoma. Dis. Markers 2014, 298795 (2014).
92. Bruchova H, Borovanova T, Klamova H, Brdicka R. Gene expression profiling in chronic myeloid leukemia patients treated with hydroxyurea. Leuk. Lymphoma 43(6), 1289-1295 (2002).
93. Zhao J, Ma MZ, Ren H et al. Anti-HDGF targets cancer and cancer stromal stem cells resistant to chemotherapy. Clin. Cancer Res. 19(13), 3567-3576 (2013).
94. Yamamoto T, Nakamura H, Liu W et al. Involvement of hepatoma-derived growth factor in the growth inhibition of hepatocellular carcinoma cells by vitamin K(2). J. Gastroenterol. 44(3), 228-235 (2009).
95. Boomgaarden I, Egert S, Rimbach G, Wolffram S, Muller MJ, Doring F. Quercetin supplementation and its effect on human monocyte gene expression profiles in vivo. Br. J. Nutr. 104(3), 336-345 (2010).
96. Merkerova M, Bruchova H, Kracmarova A, Klamova H, Brdicka R. Bmi-1 over-expression plays a secondary role in chronic myeloid leukemia transformation. Leuk. Lymphoma 48(4), 793-801 (2007).
97. Abraham NG, Scapagnini G, Kappas A. Human heme oxygenase: Cell cycle-dependent expression and DNA microarray identification of multiple gene responses after transduction of endothelial cells. J. Cell. Biochem. 90(6), 1098-1111 (2003).